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Summary 
A mathematical model is presented for the description of transdermal drug delivery from a matrix-type delivery device. The 
model is partly diffusional and partly compartmental in nature. The matrix and stratum corneum are both considered tobe diffusion 
layers, connected to a three-compartment model representing the viable epidermis/dermis, plasma, and peripheral tissues. The 
diffusion equation was solved numerically for the two diffusion layers under non-sink conditions. The ordinary differential equations 
for the compartmental model were also solved numerically. Combination of the two numerical solutions yielded a model which 
directly relates the properties ofthe matrix to the profile of drug mass in the plasma nd the urinary excretion profile. The model was 
first used to analyse data obtained from an in vivo trial of a matrix-type transdermal delivery device for the drug clenbuterol. Fitting 
of the model to the profile of drug concentration in the plasma, the urinary excretion profile, and the mass of drug remaining in the 
matrix with a modified simplex method yielded values for the model constants. These compared very favourably with independent 
values taken from the literature. Simulations of the influences of drug diffusivity within the stratum corneum, drug loading in the 
matrix, matrix thickness and drug diffusivity within the matrix on the profile of drug concentration i  the plasma were then made. 
The model is not restricted to a steady state nor does it specify particular drug release kinetics from the matrix. It does assume 
isotropic diffusion layers and spontaneous partitioning at boundaries. 
Introduction 
Transdermal drug delivery can be viewed as a 
sequence of transport and distribution processes; 
the drug is first released from its delivery device 
and passes across the skin tissues into the systemic 
circulation, from where it is excreted via the kid- 
neys into the urine (Guy and Hadgraft, 1980). The 
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resulting concentrat ion profile in the plasma for 
drugs of short pharmacokinetic half-life is prim- 
arily rate-l imited by transport across the outer- 
most skin tissue, the stratum corneum. For drugs 
of long pharmacokinetic half-life the rate of excre- 
tion is a second rate-l imiting factor (Tojo, 1988). 
These two rate-l imiting processes cannot, however, 
be realistically tailored in a controlled manner  to 
produce opt imum drug concentration profiles in 
the plasma. It is much easier to adjust the rate of 
drug release from the delivery device, by altering, 
for the example of a polymer matrix-type system, 
the matrix thickness, drug loading or drug diffu- 
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sivity within the matrix. Any model for transder- 
mal drug delivery should, therefore, show directly 
how changes in these specific properties of the 
delivery device influence the drug concentration 
profile in the plasma. 
None of the available, published models for 
transdermal drug delivery quite satisfies this ob- 
jective. Compartmental models such as that il- 
lustrated in Fig. 1 (Guy et al., 1982), although 
capable of being combined with v~--drug release 
kinetics (Hadgraft, 1990), do not recognise the 
diffusional nature of drug passage through the 
skin. This inexactitude was overcome by Tojo 
(1988), who developed an elegant combined iffu- 
sion/compartmental model, also illustrated in Fig. 
1. The non-steady-state diffusion of drug through 
the stratum corneum and viable epidermis is now 
recognised, and this transport process linked to a 
two-compartmental model representing distribu- 
tion of the drug in the plasma and peripheral 
tissues. The specific properties of the delivery de- 
vice are, however, still not considered. Indeed, the 
drug concentration at the outermost edge of the 
stratum corneum is assumed to be constant with 
this model, an assumption which is not justifiable 
and leads to simulated rug concentration profiles 
in the plasma that show a quite unrealistic 
steady-state phase. The model describes thus only 
the cases of pure skin- or pure elimination con- 
trolled transdermal drug delivery and effectively 
ignores the influence of the delivery device. 
As part of a study of the transdermal delivery 
of the drug clenbuterol we have modified and 
extended the combined iffusion/compartmental 
approach to include non-steady-state diffusion 
within a matrix-type delivery device. We feel that 
the resulting model represents a more satisfying 
description of transdermal drug delivery than other 
models currently to be found in the literature. It 
shows directly how the drug concentration profile 
in the plasma during transdermal pplication can 
be influenced not only by the properties of the 
stratum corneum and underlying tissues but also 
by the specific properties of the matrix. 
Model for Transdermal Drug Delivery 
The non-steady-state model we propose is il- 
lustrated schematically in Fig. 2 and differs in 
three crucial points from that 15ublished by Tojo 
(1988). Firstly, both the matrix and stratum 
corneum are treated as diffusion layers. This is 
necessary by virtue of their high resistances to the 
diffusional transport of drug molecules. Both 
layers are taken to be isotropic, with drug diffu- 
sion characterised only by the diffusivities D m and 
Ds, respectively. We assume thereby that the drug 
molecules traverse a direct, linear pathway through 
the whole area of the stratum corneum. As such, 
the question of intra- versus intercellular pathways 
is not considered in this paper and the non-iso- 
tropic structure of the stratum corneum is ignored. 
A spontaneous partitioning of drug at all 
boundaries i also assumed, since interracial trans- 
fer is thought unlikely to be rate-determining for 
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Fig. 1. Schematic representation of two literature models for transdermal drug delivery. (m) Delivery device; (sc) stratum corneum; 
(ve) viable pidermis; (b) plasma; (t) peripheral tissues; (D) diffusivity; (kl-ks) microconstants; (ke) elimination rate constant; (co) 
fixed drug concentration at outermost boundary ofsc. 
percutaneous absorption (Albery and Hadgraft, 
1979). The outer edge of the matrix (x = -L )  is 
insulated. If only linear diffusion with constant 
diffusivity occurs then the drug concentrations in 
the two layers, Cm(X,t ) and cs(x,t), can be de- 
scribed as functions of space, x, and time, t, by 
the one-dimensional form of Fick's Second Law 
(Crank, 1975): 
D.c(x , t )xx -C(X , t ) t=O (1) 
where the subscripts define the respective partial 
derivatives. For completeness the model also 
specifies the existence of non-sink conditions at all 
boundaries. 
We consider each of the underlying tissues of 
the viable epidermis/dermis, plasma and periph- 
eral tissues to comprise a perfectly stirred com- 
partment. In this we differ in a second point from 
Tojo (1988), who treated the viable epidermis as a 
separate diffusion layer. Although this tissue does 
comprise a distinct, morphological layer within 
the skin (Lee and Palicharla, 1986), drug diffusivi- 
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ties within both viable epidermis and dermis are 
known to be approx. 1000 times greater than those 
within the stratum corneum (Scheuplein and 
Blank, 1971) and approx. 200-1000 times greater 
than those within the polymer matrix used for this 
study (GGpferich and Lee, 1991). Furthermore, 
the dermis is permeated extensively by capillaries, 
which extend up to the junction with the viable 
epidermis. Hence, our combination of the viable 
epidermis and dermis as a single compartment. 
Within each of the three compartments only the 
time-dependent drug mass, re(t), need be defined. 
The first:order transfer of drug between the com- 
partments i characterised in the usual fashion by 
microconstants. A third difference from Tojo 
(1988) is here the use of two microconstants (k12 
and k21 ) at the boundary between the viable epi- 
dermis/ dermis compartment and the plasma. This 
allows the possible accumulation of drug external 
to this boundary, as caused, for example, by the 
retention of drug within the stratum corneum. 
Elimination from the plasma is characterised by 
k e. The change in drug mass with time within each 
x=-L x=O 
Matrix 
Om 
Cm(X,t) 
Stratum corneum 
fls 
Cs(X,t) 
x=a 7 x=a+b 
Viable epidermis & 
dermis 
Ce(t) = melt)/b 
k12 
k21 
c~ c~ 
Plasma Tissue 
rap(t) 
I k, r 1 , # 
OCm(-L't)=o I]mOCm(O't)-Os ~(O't) bdCe(t)=-Os Ocs(a't) Elimination 
Ox ax - 8x dt 8x 
cm(O.t) =Xcs(O,t) 
k23 
k32 mr(t) 
cs(x,O)=const. Ce(X,O)=const. 
t _ _ I  
0-~ "-'== 0-~1 drift) i~(a.t) b+ 
o<x<a ]l *k21mp(t)-klzme(t) ] 
Cm(X,O)=c= rap(O)= const, mdO)=const. 
-L<x,,=O -(kzl,ke*k23)mp(t)* 
*k3zmtlt) 
-k3zmr(t) 
Fig. 2. Diffusion/compartmental model for transdermal drug delivery. (x) space coordinate; (t) time; (c(x,t)) drug concentration; 
(re(t)) drug mass; (D) diffusivity; (k12, k2z, k23 , k32 ) microconstants; (k~) elimination rate constant; (Co) initial drug concentration 
in matrix. 
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compartment, dm(t)/dt, can be described by an 
ordinary differential equation of first order, as 
shown in Fig. 2. The profile of drug concentration 
in the plasma, Cp(t), is now directly related to 
matrix thickness, L, drug loading, c 0, and drug 
diffusivity within matrix and stratum corneum. 
Methods 
An analytical solution to the model is difficult 
to obtain because the Laplace transform solution 
to the double-layer diffusional problem is not easy 
to invert (G~Spferich and Lee, 1991) and the char- 
acteristic equation describing the three-compart- 
ment model with five microconstants is cubic and 
not directly solvable. A numerical solution can, 
however, readily be derived by using the Crank- 
Nicolson finite-difference method (Crank and 
Nicolson, 1947; Smith, 1987). The only complica- 
tion involved occurs at the point x --- a, where it is 
neccessary to change c(x,t) into re(t). The com- 
plete solution was programmed in Pascal on an 
Epson AX3 PC (80 386 processor with 80 387 
coprocessor). 
We first used the model to analyse some in vivo 
data obtained during the transdermal application 
of the drug of interest o us - clenbuterol - from 
a polymer matrix. Rather than make a qualitative 
comparison we undertook a simultaneous least- 
squares fit of the model to three sets of experi- 
mental data that had been obtained from a single 
patient wearing the device, viz. the profile of drug 
concentration i  the plasma, Cp(t), the profile of 
mass of drug remaining in the matrix, ram(t), and 
the profile of mass of drug excreted in the urine, 
mu(t ). An improved simplex method (Nelder and 
Mead, 1967) was used which yielded from the fit 
the best values for up to six of the model con- 
stants. Since the model has ten constants includ- 
ing the volume of distribution, Vd, we decided to 
fix the values for k23 , k32 , and k e, these being 
available for clenbuterol in a published in vivo 
study (Zimmer, 1976). Furthermore, the partition 
coefficient at x = a, K ' ,  could reasonably be as- 
sumed to be unity. The best values for the remain- 
ing model constants Dm, K, Ds, k12, k21, and V d 
were determined from the least-squares fit of the 
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Fig. 3. Fitting of experimental data of drug concentration in 
plasma, Cp(t), [coordinates] obtained from an in vivo study of 
topical application of a clenbuterol-loaded polymer matrix to 
the diffusion/compartmental model [line] (c o = 1.25 mg/2 cm2; 
L=68 /tm; K '= I ;  a=15 /tin; b=50 #m; k23=0.2  h-]; 
k32 = 0.5 h-l; k e = 0.028 h-];" A = 2 cm2). 
model to the three sets of independent, experimen- 
tal data. The accuracy of the fit could then be 
judged by comparing the results obtained for the 
fitted constants with available literature values. 
Once in possession of the model constants it 
was possible to produce simulated plasma profiles 
for clenbuterol. The influence of alteration in drug 
diffusivity within the stratum corneum, drug dif- 
fusivity within the matrix, drug loading of the 
matrix, and matrix thickness was simulated to 
yield profiles of drug concentration i the plasma 
versus time. 
Results and Discussion 
The coordinates hown in Fig. 3 are the experi- 
mentally determined values for Cp(t) obtained 
during in vivo application of a clenbuterol TTS to 
the inner arm. The curve represents the best least- 
squares fit of the model to all data for Cp(t), 
ram(t), and mu(t ). The accuracy of the fit can be 
judged by the values obtained for the model con- 
stants (Table 1), all of which are very good. The 
fitted value for Dm, for example, agrees closely 
with a literature value obtained from measurement 
of drug release from the matrix in vitro (G~Spferich 
and Lee, 1991). The value for D s is somewhat 
TABLE 1 
Values for the model constants together with equioalent literature 
values 
Model constant Value from Value from 
fit to model literature 
D m (cm 2 s -1 xl011) 1.69 2.14+_0.63 
(C O = 6% W/W) a 
D s (cm 2 s -  1 × 1012) 8.22 3.97 +_ 2.33 a 
k12 (h- 1) 1.47 not available 
k21 (h -1) 12.6 not available 
V d (1) 113 85 b 
K 0.45 not available 
a From GiSpferich and Lee (1991). 
b From Zimmer (1976). 
higher than that determined from measurements 
of drug permeation through human stratum 
corneum excised from the upper thigh (GiSpferich 
and Lee, 1991). This difference can, however, 
readily be accounted for by variation in stratum 
corneum diffusivity and thickness between indi- 
viduals and the two different body sites con- 
cerned, i.e. inner arm and thigh (Barry, 1983). It is 
at first glance surprising that the fitted value for 
k21 is larger than that for k12, as this indicates 
that the drug is accumulated somewhere within 
the system to the left of the point x = (a + b). A 
closer scrutinisation of the in vivo data showed 
that this finding is correct; after 7 days, for exam- 
ple, only some 23% of the total mass of drug 
released from the matrix could be accounted for in 
the plasma, the peripheral tissue compartment, 
and the accumulated urine. This can most readily 
be explained by postulating the accumulation of a 
substantial amount of drug within the stratum 
corneum. Finally, the value obtained for V d is also 
in close agreement with its literature value 
(Zimmer, 1976). 
Our knowledge of the model microconstants 
now allows the effects of changes in these parame- 
ters on the plasma concentration profile to be 
simulated. Clenbuterol has a relatively long 
pharmacokinetic half-life of approx. 33 h (Zimmer, 
1976). According to Tojo (1988) the plasma con- 
centration profile of such a drug during transder- 
mal delivery should be controlled mainly by this 
low rate of elimination. The simulations hown in 
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Fig. 4 illustrate, however, that the profile of drug 
concentration in the plasma, Cp(t), is still very 
sensitive to change in diffusivity within the stra- 
tum corneum, D S. The curves are simulated here 
over a realistic application period for a transder- 
mal device of 7 days: each shows an initial lag 
time, reflecting non-steady-state diffusion through 
the stratum corneum. Compartmental models fail 
to illustrate this effect exactly (Guy et al., 1982), 
since they are perforce steady-state in nature. 
Noteably, none of the curves reaches a 'plateau' 
during the 7 days. This can only be observed by 
extending the simulation time substantially. Thus, 
Fig. 5 shows a simulation up to 56 days based on 
the results obtained from the fitting of the in vivo 
data. This simulated profile reaches a maximum 
(/max), after which it declines, reflecting thereby 
the continual decrease in rate of drug release out 
of the polymer matrix with time. The error associ- 
ated with an unrealistic steady-state phase as seen 
with Tojo's model (1988) is, therefore, avoided. 
The tma x of approx. 21 days seen here for clen- 
buterol is much longer than that found for cloni- 
dine during transdermal application in vivo (ap- 
prox. 2 days; Arndts and Arndts, 1984). This 
arises from the much smaller stratum corneum 
diffusivity for clenbuterol compared to clonidine 
(the latter, 2 x 10 -1° cm 2 s -1 according to Tojo, 
1988) and the likely accumulation of clenbuterol 
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Fig. 4. Simulation of the influence of drug diffusivity in 
stratum corneum (Ds) on drug concentration in plasma, cp(t) 
(Dm=4Xl0-1] cm 2 s-l; c0=6% w/w; K=I;  K '= I ;  L= 
200 #m; a=10 gin; b=50 gin; k12=1.47 h-l; k21=12.6 
h- l ;  k23 = 0.2 h - l ;  k32 = 0.5 h - l ;  k e = 0.028 h - l ) .  
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Fig. 5. Extended simulation for transdermal delivery of clen- 
buterol based on in vivo fit (Dm=1.69X10 -]1 cm 2 s - l ;  c o = 
1.25 mg/2  cm2; K=I ;  Ds=8.22X10 -12 cm 2 s - l ;  K '= I ;  
L=68 #m; a =15/~m; b=50 #m; k12 =1.47 h - l ;  k21 =12.6 
h - I ;  k23=0.2 h - l ;  k32=0.5 h - l ;  ke=0.028 h - l ;  A=2 
cm2). 
within the epidermis as indicated by the current 
study. 
The dependency of Cp(t) on D s illustrates one 
possible source for the fluctuations often observed 
in drug plasma levels during transdermal dminis- 
tration. With the drug in question diffusivities in 
the range of 1.2-6.5 × 10 -12 cm 2 s -1 have been 
reported for stratum corneum excised from the 
upper thigh of a single cadaver (G~Spferich and 
Lee, 1991). This scatter is taken to arise from the 
natural variation in the non-isotropic composition 
of the stratum comeum. It is clear from Fig. 4 that 
variation in D s within this range would lead to 
substantially differing Cp( t )  profiles. 
The effects of drug diffusivity within the ma- 
trix, D m (Fig. 6a), are much less spectacular than 
those observed for D s. It is clear that alteration of 
this property of the matrix to manipulate trans- 
dermal drug delivery is limited in scope. The ad- 
dition of plasticiser to the polymer matrix used 
here can, for example, readily increase D m for 
clenbuterol by an order of magnitude from 2 x 
10 -12 to 2 X 10 -11 cm 2 S -1. This would have, 
however, only a small effect on Cp(t) .  The simu- 
lated profiles shown in Fig. 6b illustrate dearly 
the linear dependence of cp(t) on drug loading in 
the matrix. This property of the matrix has, there- 
fore, a stronger influence on Cp(t )  than does D m, 
but is, of course, limited by the solubility of the 
drug in the matrix ( -  10% w/w for clenbuterol). 
The thickness of the matrix (Fig. 6c) has negligible 
influence on Cp(t ) ,  in agreement with previously 
published findings (Guy and Hadgraft, 1980). 
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